trump prescription drug prices

Lowering Prescription Drug Prices: A Battle of Policies and Priorities

Main Narrative

As the ongoing debate on the high cost of prescription drugs continues, the Trump administration's actions have sparked significant attention in the United States. In a move seen as a reversal of the previous administration's efforts, President Donald Trump has rolled back a rule aimed at lowering prescription drug costs for millions of Americans.

The Biden-Harris rule, as it was known, directed Medicare and Medicaid agencies to test models that could both lower prescription drug prices and make cell and gene therapy treatments more accessible to Medicaid recipients. This move was seen as a crucial step in addressing the high cost of prescription drugs, which has become a major concern for many Americans.

However, in a recent development, President Trump has rescinded this rule, leaving many wondering about the future of prescription drug prices in the United States. This article will delve into the details of this policy reversal, explore its significance, and examine the broader implications of this move.

Recent Updates

The most recent updates on this issue come from the Democrats' news report, which states:

"Donald Trump Rolls Back Biden-Harris Rule to Lower Drug Costs for Millions of Americans" [1]

According to this report, President Trump has ended the program to lower prescription prices and make disease therapy available. This move has been met with criticism from many, who see it as a step backward in addressing the high cost of prescription drugs.

Another report by the Alabama Political Reporter states:

"Trump ends program to lower prescription prices, make disease therapy available" [2]

This report provides more details on the Trump administration's actions, stating that the president has rescinded the rule aimed at lowering prescription drug costs.

Contextual Background

The issue of high prescription drug costs has been a long-standing concern in the United States. Americans pay more per capita for prescription drugs than residents of any other developed country in the world. This has led to calls for action from policymakers, healthcare advocates, and patients themselves.

In 2020, President Donald Trump signed Executive Order 13948, which aimed to lower drug prices by putting America first. This order was seen as a significant step in addressing the high cost of prescription drugs.

However, the Biden administration took a different approach, signing Executive Order 14087, which aimed to develop programs to lower prescription drug prices in the United States. This order was seen as a more comprehensive approach to addressing the issue of high prescription drug costs.

Immediate Effects

The immediate effects of the Trump administration's policy reversal are still unclear. However, it is likely that this move will have significant implications for the healthcare industry and patients themselves.

One potential consequence of this move is that it may lead to increased costs for patients, particularly those who rely on Medicaid to access prescription medications. This could have significant social and economic implications, particularly for low-income individuals and families.

Another potential consequence is that it may lead to a decrease in the availability of certain medications, particularly those that are only available through Medicaid. This could have significant health implications for patients who rely on these medications to manage their conditions.

Future Outlook

The future outlook for prescription drug prices in the United States is uncertain. However, it is likely that this issue will continue to be a major concern for policymakers, healthcare advocates, and patients themselves.

One potential outcome is that the Trump administration's policy reversal will lead to increased pressure on Congress to pass legislation aimed at addressing the high cost of prescription drugs. This could lead to the passage of a comprehensive bill that addresses the root causes of high prescription drug costs.

Another potential outcome is that this move will lead to increased polarization on the issue of high prescription drug costs. This could lead to a stalemate in Congress, making it more difficult to pass legislation aimed at addressing this issue.

Conclusion

The Trump administration's policy reversal on prescription drug prices has significant implications for the healthcare industry and patients themselves. While the immediate effects of this move are still unclear, it is likely that it will lead to increased costs for patients and decreased availability of certain medications.

However, this issue is far from over. Policymakers, healthcare advocates, and patients themselves will continue to push for action to address the high cost of prescription drugs. The future outlook for this issue is uncertain, but one thing is clear: the debate on prescription drug prices will continue to be a major concern for Americans for years to come.

[1]

References

[1] Democrats. (2023). New: Donald Trump Rolls Back Biden-Harris Rule to Lower Drug Costs for Millions of Americans.

[2] Alabama Political Reporter. (2025). Trump ends program to lower prescription prices, make disease therapy available.

[3] Newsweek. (2023). Donald Trump's Medicare Executive Order Explained.

[4] Administration of Donald J. Trump, 2020. Executive Order 13948—Lowering Drug Prices by Putting America First.

[5] TheStreet. (2025). Trump Rescinds Medicare Drug Executive Order.

[6] FactCheck.org. (2023). Trump's Executive Orders on Prescription Drugs.

[7] President Trump. (2023). Trump Signs New Executive Order On Prescription Drug Prices.